Sigma Healthcare (SIG) reports a small beat for FY22
SIG +1.92%: Sigma is a chemist retailer operating under brands like Amcal and they also have a large wholesale business, although smaller than it once was after losing the contract to supply Chemist Warehouse a few years ago. They released FY22 results today and presented to us this afternoon. We haven’t really looked at SIG before and find it hard to get excited about the stock right now, although it is in turnaround mode. Today’s result was in line with both guidance and market expectations, FY22 underlying EBITDA of $92.1m was +10.8% on last year and compared to guidance of +10-15%. No FY23 guidance, but expects to return to profit in the period.
MM has no real interest in SIG
Add To Hit List
